Lynparza stalls pancreatic cancer in patients with BRCA mutations: study

AstraZeneca and Merck & Co's Lynparza helped patients with advanced pancreatic cancer who carry BRCA gene mutations go longer without their disease worsening than those who received a placebo, according to data from a late-stage clinical trial presented on Sunday.

from Reuters: Health News https://reut.rs/2JQSqHp
via IFTTT